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Late regulation of immune genes 
and microRNAs in circulating 
leukocytes in a pig model of 
influenza A (H1N2) infection
Louise Brogaard1, Peter M. H. Heegaard1, Lars E. Larsen2, Shila Mortensen1,*, 
Michael Schlegel3, Ralf Dürrwald3 & Kerstin Skovgaard1
MicroRNAs (miRNAs) are a class of short regulatory RNA molecules which are implicated in modulating 
gene expression. Levels of circulating, cell-associated miRNAs in response to influenza A virus (IAV) 
infection has received limited attention so far. To further understand the temporal dynamics and 
biological implications of miRNA regulation in circulating leukocytes, we collected blood samples 
before and after (1, 3, and 14 days) IAV challenge of pigs. Differential expression of miRNAs and innate 
immune factor mRNA transcripts was analysed using RT-qPCR. A total of 20 miRNAs were regulated 
after IAV challenge, with the highest number of regulated miRNAs seen on day 14 after infection at 
which time the infection was cleared. Targets of the regulated miRNAs included genes involved in 
apoptosis and cell cycle regulation. Significant regulation of both miRNAs and mRNA transcripts at 14 
days after challenge points to a protracted effect of IAV infection, potentially affecting the host’s ability 
to respond to secondary infections. In conclusion, experimental IAV infection of pigs demonstrated the 
dynamic nature of miRNA and mRNA regulation in circulating leukocytes during and after infection, and 
revealed the need for further investigation of the potential immunosuppressing effect of miRNA and 
innate immune signaling after IAV infection.
Influenza A virus (IAV) infections are widespread in the human population and have great impact on human 
health and welfare. Significant resources are linked to influenza epidemics due to excess hospitalizations and 
lost productivity in workplaces, as well as the need for the production of yearly updated vaccines to cover the 
currently circulating influenza virus strains1. Otherwise healthy subjects will recover within 1–2 weeks without 
treatment, but the infection may also lead to severe morbidity and mortality, especially in elderly and immune 
compromised individuals2. New strains of influenza virus with pandemic potential will continue to emerge due 
to mutation, genetic reassortment, and a complex animal reservoir.
MicroRNAs (miRNAs) are a class of short (~22 nt), endogenous regulatory RNAs that have been identified 
in a wide range of organisms, including animals, plants, viruses, and fungi3. They modulate gene expression 
by interfering with mRNA translation most commonly by destabilising mRNA thereby facilitating degradation. 
miRNA-mRNA target interactions are complex; one miRNA may target a large number of genes, and the targets 
of a miRNA may belong to a variety of functional groups3. In turn, the 3′ -UTR of a single mRNA transcript may 
be the target for several different miRNAs, lending another layer of complexity as well as flexibility to the system. 
miRNA-mediated regulation of gene expression has been found to affect many cellular functions, including innate 
and antiviral responses, e.g. key innate immune pathogen recognition receptors (PRRs) such as Toll-like receptors 
(TLR) and RIG-I-like receptors (RLR) and their associated pathways4. Additionally, a number of miRNAs have 
been demonstrated to bind to influenza virus PB1 mRNA and inhibit viral replication in vitro5. Recently, locally 
expressed miRNAs in lung tissue have been found to be regulated in response to IAV infection in pigs, chickens, 
mice, and macaques6–10, but until now only three studies have investigated the role of circulating miRNAs during 
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IAV infection11–13. These studies investigated human patients and each study employed a different type of sam-
ple material, namely whole blood11, peripheral blood mononuclear cells (PBMCs)12, and serum13 from human 
patients, respectively. It is however important to recognize that circulating miRNAs may originate from different 
sources; white blood cells, red blood cells, and platelets all contain miRNAs. But miRNAs are also found extracel-
lularly in protein complexes (Argonaute, RNA-induced silencing complex (RISC)), extracellular vesicles (EVs), 
and associated with high-density lipoprotein14,15. The origin of cell-free circulating miRNAs is still unclear; they 
may be breakdown products originating from lysed cells, or they may be actively secreted from cells to act in a 
paracrine manner, or perhaps a combination of the two14. Regulation of cell-associated and cell-free miRNAs 
in circulation in response to IAV infection may thus have different causes and functions. In PBMCs of critically 
ill patients with H1N1 infection, expression of hsa-miR-29a, -31, and -148a were all determined individually 
to have diagnostic potential12, whereas the serum levels of hsa-miR-17, -20a, -106a, and -376c in combination 
could discriminate between avian influenza infected patients and healthy controls13. The third study, employing 
whole blood, reported some overlap with findings from the PBMC and serum studies, namely hsa-miR-29a and 
hsa-miR-17 and -106a, respectively11. Current knowledge on miRNAs in circulation in response to IAV is thus 
based on few studies representing both cell-free and cell-associated miRNAs.
All three studies have identified miRNAs that are regulated during IAV infection in human patients. An inher-
ent challenge in such observational studies, however is that the timing of the infection is unknown; the infection 
could be widely differently progressed in the patients included. In contrast, animal models allow for precise 
control of parameters such as time and dose. An ideal animal model for human influenza should reproduce 
the clinical signs and pathogenesis observed in human influenza disease, and the host response should mimic 
that observed in humans, including an efficient antiviral immune response. The general potential of the pig as 
a large animal model for human disease including influenza has been reviewed several times16–18. Specifically, 
fever, fatigue, lassitude, and cough, which were the best indicators of human influenza in several studies19–21, are 
all induced in IAV infected pigs within the first three days of infection as shown by us and others6,22–24. Pigs are 
susceptible to infection with human influenza A viruses, and have been demonstrated to be involved in influenza 
evolution and ecology18,25. Pigs additionally share many similarities with humans with respect to tracheobron-
chial tree structure, influenza virus receptor distribution, lung physiology, and innate immune cell infiltration 
of the respiratory system26–29. The pig is thus an obvious large animal model for human respiratory infections. 
However, the use of the mouse as an animal model for human IAV infection has been instrumental in influenza 
research due to its low cost, broad range of available reagents, and the availability of genetically modified mice30,31. 
Although this classical model has provided important information about basic biology during viral infection, 
mice are not natural hosts for IAV and many important clinical signs characteristic of human influenza virus 
infection are absent in mice31. The ferret model has also contributed substantially to the understanding of e.g. 
IAV pathogenicity, and transmission as well as species and cell tropism, in large part thanks to the ferret being 
susceptible to human IAV strains30. However, little is known about ferret specific innate immune response to IAV 
infection30,31. Table 1 summarizes some of the most important similarities and differences between man, pig, and 
mouse with regards to their clinical and immunological responses to IAV infection.
Despite the great potential of the pig as a large animal model and the importance of pigs in evolution and 
transmission of IAV, the immune response of pigs against IAV is not fully understood. This study aimed at provid-
ing a better understanding of the involvement of circulating miRNAs and innate immune factors in porcine blood 
leukocytes during and after active IAV infection. We focused on the cell-associated miRNA and mRNA expres-
sion. Cells in the lungs produce chemokines in response to IAV infection which direct the recruitment of various 
immune cells from the blood stream into the infected lung tissue6,32. miRNA expression profiles of circulating 
leukocytes may thus be important for immune regulation in the lung during IAV-infection, or even during sub-
sequent secondary infections. Our experimental setup allowed us to perform highly controlled experimental IAV 
infection of pigs, and to study development of disease signs, viral titre, and fluctuations in miRNA and mRNA 
Symptom/characteristic Human Pig Mouse Reference
Fever Present Present Absent 19,54
Nasal secretion Present Present Absent 54
Coughing Present Present Absent 19,21
Major sialic acid receptor of the upper 
respiratory tract α2-6-linked α2-6-linked α 2-3-linked
25,55,56
Possess tonsils Yes Yes No 57
Nature of connective tissue Extensive and interlobular Extensive and interlobular Little if any 26,27
Nature of pleurae Thick Thick Thin 26
Early cytokine response to IAV 
infection Very similar to humans
Somewhat similar to 
humans
6,20,23,24,28
Pulmonary intravascular macrophages Induced phagocytic cells Constitutive phagocytic cells Induced phagocytic cells 58
Lymph node structure Inverted As humans 17
Interleukin 8 Present Present No direct homolog 59,60
Immunological reagents available Many Increasing Many 30,31
Table 1.  Major differences and similarities of human, pig, and mouse disease signs, physiology, anatomy 
and immunology with regards to influenza A virus infection.
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levels as the disease progressed in time based on a statistically useful number of pigs, generating important infor-
mation relevant for human disease, which would be difficult to obtain from human patients.
Results
Infection model and clinical signs. Clinical signs and results from virus specific qPCR from lung samples 
and nasal swabs of infected animals have been reported previously6. This included abrupt onset of disease with 
dyspnoea, fatigue, nasal secretion and nasal viral excretion on day 1 pi. Fever > 40 °C was seen for all but one pig 
(39.6 °C) on day 1 pi. Clinical signs peaked between day 1 and 2 pi. Between day 3 and 7 pi coughing occurred in 
individual pigs. The infection and disease were completely cleared at day 14. Lung virus titres peaked at day 1 pi; 
mean log10 EID50/g lung tissue was 4.23 and 3.35 at day 1 and 3 pi, respectively. No virus could be detected in the 
lungs by day 14 pi.
Quantification of leukocyte miRNAs in circulation. An initial screening for changes in miRNA expres-
sion in leukocytes at 24 and 72 h pi compared to before challenge was performed using the miRCURY LNA 
Human Panel I (Exiqon) assaying 375 human miRNAs. Of these, approx. one third was quantifiable in porcine 
leukocytes; however, only five were significantly differentially expressed (one-way ANOVA): hsa-miR-223-5p 
(p = 3.20E-07), hsa-miR-23a-3p (p = 0.0001), hsa-miR-30c-5p (p = 1.10E-07), hsa-miR-150-5p (p = 0.0002), and 
hsa-miR-92b-3p (p = 0.0005).
Results from the miRCURY LNA screening revealed the need for a more tailored approach; relevant miRNAs 
were selected for expression analysis in a larger set of samples, using the high-throughput RT-qPCR platform 
BioMark (Fluidigm). This selection included several of the miRNAs assayed in the miRCURY LNA Human Panel 
I, including four of the five miRNAs that were significant on the miRCURY platform. Using Student’s t-test or 
Mann-Whitney U test (p < 0.05) to determine statistical significance of biologically relevant alterations in expres-
sion level (> ± 1.5 fold up- or down-regulation) showed that results obtained from the two qPCR platforms were 
in agreement (data not shown).
Using high-throughput RT-qPCR we found a total of 20 miRNAs to be differentially expressed in IAV chal-
lenged pigs at minimum one of the three post-challenge sampling points compared to before challenge as depicted 
in the heat map in Fig. 1a; the precise expression levels relative to before challenge can be found in Supplementary 
Table S3. Only four miRNAs (hsa-miR-223-5p, ssc-miR-31, ssc-miR-29a, and ssc-miR-182) were differentially 
expressed at 24 h pi, whereas 10 miRNAs were differentially expressed at 72 h pi (ssc-miR-29b, hsa-miR-203a-3p, 
hsa-miR-449a, ssc-miR-21, ssc-miR-29a, hsa-miR-23a-3p, ssc-miR-23b, ssc-miR-30c-5p, ssc-miR-423-5p, and 
hsa-miR-150-5p). However, the highest number of significantly regulated miRNAs compared to before chal-
lenge was found at 14d pi, at which time point the infection had completely cleared (ssc-miR-15a, ssc-miR-29b, 
ssc-miR-29a, hsa-miR-449a, ssc-miR-186, ssc-miR-22-5p, ssc-miR-28-5p, hsa-miR-203a-3p, ssc-miR-146a-5p, 
hsa-miR-150-5p, ssc-miR-23b, hsa-miR-223-3p, hsa-miR-23a-3p, hsa-miR-16-5p). In all three post-challenge 
groups, at least three miRNAs were found to be unique for that particular time point, and only ssc-miR-29a was 
found to be differentially expressed at all three examined time points. Overlaps and differences in miRNA regu-
lation at the three time points are summarised in Fig. 1b.
Leukocyte immune gene expression. In contrast to miRNA regulation, the major changes in immune 
gene expression were seen at 24 h pi. Levels of expression of interferon and interferon-induced genes, pattern 
recognition receptors (PRRs), chemokines, and pro- and anti-inflammatory cytokines before and after infection 
are listed in Table 2. We were able to verify expression of genes found to be regulated in human IAV infection 
such as CCL2, CXCL10 (IP-10), MX1, OASL, STAT1, IFIH1 (MDA5), and DDX58 (RIG-I) in our porcine model. 
These genes have been previously reported to be of considerable diagnostic value in human influenza studies33–36. 
Remarkably, all of these genes but CCL2 were among the most highly expressed immune factors in the present 
study at 24 h pi (Table 2). Several RNA virus associated PRRs, including DDX58, IFIH1, TLR7, and TLR8, were 
regulated according to infection status, being up-regulated at 24 h pi, and showing little or negligible change in 
expression during the rest of the study. Surprisingly, we found the PRR TLR4, recognising bacterial LPS, to be 
the most highly up-regulated TLR at 24 h pi. The up-regulation of IDO1 (more than 100 fold after 24 h) was also 
highly significant and in agreement with the overall pattern of increased expression of pro-inflammatory genes, 
characterised by a fast and transient up-regulation peaking at 24 h pi (Table 2). Importantly, at day 14 pi all sig-
nificant differentially expressed immune genes were down-regulated; these late down-regulated genes included 
CCL3, CXCL2, IL1RAP, IL18, PTSG2, TNF, IDO1, TLR3, and TLR4. The most significant down-regulation was 
seen for IL18 at 24 h pi. This was also the only gene that was significantly down-regulated at all three time points.
Identification of targets of regulated leukocyte miRNA. KEGG pathway enrichment analysis of the 
validated gene targets of the 20 differentially expressed miRNAs revealed a big overlap in pathways enriched 
in the four subsets of target genes. Significantly enriched “p53 signaling”, “Cell cycle”, “Apoptosis”, as well as 
pathways related to immune response and leukocyte extravasation, e.g. “Cytokine-cytokine receptor signaling”, 
“Chemokine signaling”, “Jak-STAT signaling”, “Focal adhesion”, “Adherens junction”, and “Tight junction”. In 
addition, several cancer related pathways were identified as significantly enriched as well, possibly due to many 
of the gene targets being involved in apoptotic and anti-apoptotic processes, as will be discussed later. A list of 
significantly enriched pathways can be found in Supplementary Table S4.
Differentially expressed miRNAs (human homologs) and experimentally validated MTIs (obtained from miR-
TarBase) were submitted to Cytoscape, creating interaction networks for all three post-infection time points. Of 
the 20 examined miRNAs, only two (hsa-miR-223-5p and hsa-miR-22-5p) did not have any MTIs registered in 
miRTarBase. At all three time point, we found a large number of genes to be targeted by only one of the regu-
lated miRNAs (see Supplementary Fig. S1), but also genes targeted by two or more miRNAs were present in the 
www.nature.com/scientificreports/
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interaction networks at all three time points. The number of genes with two or more experimentally validated 
MTIs comprised 6, 65, and 84 at 24 h, 72 h, and 14d pi, respectively (see Supplementary Fig. S1).
miRNA target gene expression. Following MTI analysis, a subset of genes found to be targets for 
regulated miRNAs were subjected to transcriptional analysis. A complete list of genes can be found in 
Supplementary Table S1. The following genes were found to be significantly (however less than 2-fold) up- or 
down-regulated compared to before challenge: at 24 h pi – BCL2, MCL1, and SP1 (up-regulated), IFNG, PTEN 
and CXCR4 (down-regulated); at 72 h pi – VEGFA (up-regulated), CCNE2 (down-regulated); at 14d pi – VEGFA 
(up-regulated); CCNE2 and PTEN (down-regulated). Additionally, the following genes showed no significant 
differential expression: CDK2, CDK4, FOXO3A, TP53, CASP9, CHUK, and AKT2.
Figure 1. Expression of miRNA in porcine leukocytes after IAV challenge. (a) clustered heat map depicting 
up- and down-regulation (red and blue, respectively) at 24 h, 72 h, and 14d pi compared to before challenge. 
*Indicates statistical significance at that time point. †Indicates that the miRNA have previously been reported to 
be regulated in circulation in human patients after IAV infection11–13. Human (hsa-) miRNAs: hsa-miR-223-3p, 
hsa-miR-223-5p, hsa-miR-203a-3p, and hsa-miR-449a are not yet annotated in the porcine genome. hsa-miR-
150-5p, hsa-miR-16-5p, and hsa-miR-23a-3p were not annotated in the pig genome at the time the assay was 
designed, but sequences have since become available and found to be 100% identical to the human homologs 
that were used for primer design. (b) Venn diagram showing at which post challenge time points miRNAs were 
regulated compared to before challenge.
www.nature.com/scientificreports/
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Discussion
Similarities and differences between human, pig, and mouse with regard to influenza and factors of importance 
for development of influenza are highlighted in Table 1. It is evident based on both physiological and immunolog-
ical considerations, that the porcine model has the potential to provide valuable information in the study of IAV 
infection18,28. We did indeed observe clinical signs in the animals post challenge highly similar to those observed 
during human IAV infection6. We were able to reproduce key findings of human coding and non-coding tran-
scriptional responses to IAV infection, consolidating the pig as a relevant large animal model for the study of IAV 
infection in controlled settings.
Early cytokine responses to IAV infection have been found to be remarkably similar between humans and 
pigs6,20,23,24. In the present study we found blood-based gene expression profiles of both coding and non-coding 
Gene
Before challenge 





















CASP1 1.00 0.13 7.21 1.78 4E-12 2.18 0.58 0.00022 0.94 0.36 NS
CASP3 1.00 0.09 5.91 1.07 3E-13 1.36 0.35 NS 1.13 0.30 NS
CCL2* 1.00 0.41 2.34 0.50 0.0012 1.63 0.56 NS 1.53 0.70 NS
CCL3 1.00 0.24 0.59 0.22 0.030 1.07 0.70 NS 0.52 0.17 0.0067
CD163 1.00 0.47 3.58 1.50 0.00015 2.73 2.09 NS 0.48 0.18 0.047
CXCL2 1.00 0.35 0.96 0.18 NS 0.99 0.78 NS 0.39 0.16 0.019
CXCL10* 1.00 0.33 283 92.56 7E-16 5.84 4.39 0.011 3.43 5.81 NS
DDX58* 1.00 0.23 13.01 2.01 6E-13 1.53 0.66 NS 0.64 0.42 NS
FAS 1.00 0.11 5.52 1.02 4E-12 0.94 0.24 NS 0.73 0.19 0.018
FASLG 1.00 0.39 2.42 0.62 0.026 1.06 0.57 NS 0.65 0.23 NS
IDO1 1.00 0.30 133 98.20 8E-09 0.71 0.28 NS 0.55 0.27 0.035
IFITM1 1.00 0.27 5.66 0.98 2E-10 1.62 0.49 0.040 0.81 0.24 NS
IFITM3 1.00 0.40 3.93 0.69 7E-8 1.56 0.54 NS 0.78 0.27 NS
IFNA1 1.00 0.26 2.86 1.32 0.0022 0.72 0.23 NS 1.31 0.59 NS
IL8 1.00 0.32 1.86 0.60 0.018 1.37 0.44 NS 1.17 0.20 NS
IL10 1.00 0.39 4.49 1.04 2E-06 1.55 0.40 NS 0.93 0.23 NS
IL18 1.00 0.28 0.09 0.04 3E-08 0.60 0.52 0.020 0.50 0.28 0.028
IL1RAP 1.00 0.34 9.24 2.32 8E-09 0.70 0.32 NS 0.41 0.22 0.014
IL1RN 1.00 0.27 18.14 3.56 3E-14 1.10 0.29 NS 0.97 0.23 NS
IRF1 1.00 0.19 1.80 0.31 0.00030 0.57 0.13 0.0015 0.75 0.26 NS
IRF2 1.00 0.16 4.66 0.81 2E-10 1.09 0.25 NS 0.78 0.19 NS
IRF3 1.00 0.21 2.45 0.48 3E-06 0.99 0.18 NS 0.66 0.15 0.033
IRF9 1.00 0.25 1.88 0.25 0.00011 0.95 0.17 NS 0.72 0.22 NS
IFIH1* 1.00 0.20 5.37 0.73 3E-11 1.15 0.22 NS 0.80 0.30 NS
JAK2 1.00 0.17 3.79 0.88 2E-8 1.35 0.30 NS 1.10 0.36 NS
MCL1 1.00 0.20 2.06 0.26 4E-06 0.90 0.17 NS 0.82 0.13 NS
MX1* 1.00 0.23 13.72 2.09 1E-13 2.10 0.70 0.0018 0.87 0.65 NS
MYD88 1.00 0.28 1.58 0.39 0.031 0.90 0.44 NS 0.61 0.23 NS
NOD1 1.00 0.23 2.55 0.36 7E-5 1.08 0.25 NS 0.74 0.09 NS
OASL* 1.00 0.26 20.40 4.14 7E-12 2.11 1.06 NS 1.20 1.10 NS
PTGS2 1.00 0.26 1.33 0.28 NS 0.87 0.23 NS 0.39 0.12 0.0012
STAT1* 1.00 0.09 4.13 0.46 8E-14 1.11 0.25 NS 0.88 0.25 NS
TICAM1 1.00 0.25 2.47 0.66 0.00016 1.47 0.43 NS 1.08 0.29 NS
TICAM2 1.00 0.19 3.30 0.69 2E-08 0.84 0.14 NS 0.58 0.11 0.0017
TLR2 1.00 0.34 2.30 0.45 0.00035 1.12 0.52 NS 0.81 0.32 NS
TLR3 1.00 0.23 2.42 0.48 4E-05 1.40 0.35 NS 0.51 0.12 0.0078
TLR4 1.00 0.26 8.41 2.90 8E-09 1.32 0.64 NS 0.56 0.26 0.023
TLR7 1.00 0.14 4.23 0.51 4E-12 1.34 0.34 NS 1.09 0.34 NS
TLR8 1.00 0.22 2.17 0.59 0.00014 1.77 0.34 0.00065 1.11 0.22 NS
TNF 1.00 0.21 0.55 0.15 0.0027 0.79 0.42 NS 0.35 0.11 0.00024
Table 2.  Relative expression levels of immune gene mRNA transcripts in porcine leukocytes before IAV 
challenge and at 24 h, 72 h, and 14d pi. Genes included are all statistically significantly > 2-fold up- or down-
regulated at at least one time point after challenge (p < 0.05); NS: not significant. Genes marked with * have 
previously been reported as classifiers for human IAV infection (H1N1, H3N2)33–37.
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RNA to be tightly regulated in accordance with progression of infection and disease in pigs experimentally 
infected with the H1N2 influenza virus. Expression of several protein coding genes in whole-blood RNA from 
human patients or volunteers have been found to be good predictors for IAV infection33–37. These genes include 
CXCL10 (IP-10), MX1, OASL, STAT1, IFIH1 (MDA5), and DDX58 (RIG-I), and CCL2, which we also found to be 
highly expressed shortly after experimental IAV infection in pigs. Likewise, the expression of porcine interferon 
(IFNA1 and IFNG) and interferon-related genes after viral infection were highly similar to those seen in human 
influenza cases35–37.
We and others have reported locally produced miRNAs in lung tissue to be differentially expressed in response 
to IAV infection in a number of different animal models6–10. However, expression signatures of miRNAs in circu-
lation after IAV infection have only been reported in a few studies11–13. These studies have employed whole blood, 
PBMCs, or serum supplied by hospitalised patients and healthy volunteers and the results therefore represent the 
circulating miRNA response to IAV infection collected from individuals that may have had widely differently 
progressed disease, and from blood fractions that may carry very different miRNA profiles even before IAV infec-
tion. However, 13 of the 20 differentially expressed miRNAs identified in the present study have been reported 
in the abovementioned human studies as relevant for distinguishing between healthy controls and IAV infected 
patients11,12 (Fig. 1a). Almost complete sequence conservation is seen between human and porcine homologs of 
these miRNA, also within the important seed sequences (Supplementary Table S2). It is therefore reasonable to 
expect these conserved miRNAs to have the same biological function in response to IAV infection in pigs and 
humans.
Our experimental setup proved useful for demonstration of the temporal dynamics of miRNA expression after 
IAV challenge, from the first days of infection to after the IAV infection had cleared. In contrast to the human 
studies, the pig model allowed us to demonstrate that there is indeed a time factor to consider when assessing 
the regulation and involvement of cell-associated circulating miRNAs in response to IAV infection. This is made 
evident by our observations of e.g. ssc-miR-29a expression; this miRNA is initially down-regulated (24 h pi) but 
later up-regulated (72 h and 14d pi) (Fig. 1a), whereas human studies have reported only down-regulation of its 
homolog hsa-miR-29a-3p11–13. Another miRNA identified in human studies as regulated after H1N1 infection is 
hsa-miR-150-5p which was reported by one study to be up-regulated11 while it was found to be down-regulated 
in another study12. We found that hsa-miR-150-5p was down-regulated in porcine leukocytes 72 h and 14d after 
H1N2 challenge in pigs (Fig. 1a). Many factors other than host species may contribute to these differences, e.g. 
the lack of control of the infection progression in human patient studies, patient heterogeneity, difference in IAV 
subtypes, and the application of different blood components in the analyses. Still, time course studies of miRNA 
expression in controlled experimental settings using standardised sampling methods are able to provide impor-
tant data when studying the role of miRNAs in circulation in response to infection and in the search for valid 
biomarkers.
Genes for several well-known PRRs and pro-inflammatory factors were significantly down-regulated at day 
14 pi, after the viral infection had cleared (Table 2). These data suggest a persisting lowered immune responsive-
ness in the animal. Critical illness and severe sepsis have previously been shown to leave patients in a protracted 
immunosuppressed stage after the illness has passed38, but here we show that even a mild course of influenza 
disease may transcriptionally affect the immune competence of the recovered animal. Likewise, expression of 
miRNA at day 14 pi with the potential to subtly affect and regulate important apoptosis and cell survival related 
processes may have an essential function in the case of secondary infections following IAV infection. Upon sec-
ondary infection, circulating leukocytes will be recruited to the site of infection, and their built-in arsenal of 
apoptosis-regulating miRNAs could thus greatly influence disease progression.
Studies of secondary bacterial infections in mice after IAV infection have demonstrated a desensitisation to 
TLR ligands even several months after the IAV had cleared39. This appears to be a strategy for avoiding excessive 
inflammation, but the consequence of this lowered responsiveness may also be increased susceptibility to sec-
ondary infections. Here we show that ssc-miR-146a-5p is significantly up-regulated in circulating leukocytes 
only at 14d pi; the human homolog of this miRNA has been found to target important components of TLR sig-
naling, such as TLR2, TLR4, NFKB1, IRAK1, TRAF6, and IL8. hsa-miR-203a-3p, which targets MYD88, is also 
up-regulated at 14d pi. These miRNAs might contribute to the reported lack of responsiveness to bacterial TLR 
ligands, by inhibiting translation or increasing degradation of mRNA transcripts of key components in the TLR 
signaling pathway. Strikingly, we did observe that TLR4 and TNF (targets of and miR-146a-5p and miR-203a-3p, 
respectively) were significantly down-regulated in leukocytes at 14d pi. It is also worth noting, that in contrast to 
most other pathways found to be enriched in our analysis of miRNA target genes, the Toll-like receptor signaling 
pathway was only enriched in gene targets of up-regulated miRNAs, suggesting that TLR-mediated signaling may 
mostly be suppressed. The long-term effect of IAV-infection on the miRNA expression profile of circulating leu-
kocytes thus potentially affects the individual’s ability to combat secondary infections. This calls for future studies 
and focused investigation to elucidate if the miRNAs of circulating white blood cells truly affects the immune 
response to secondary infections, and offers a potential therapeutic target to avoid excess morbidity and mortality 
in vulnerable populations.
Both host and viral factors may contribute to the late regulation of miRNAs in circulating leukocytes at 14d 
pi. IAV is known to produce defective interfering (DI) virus particles during infection, i.e. virus particles that are 
unable to complete a full replication cycle but may be able to replicate in the host cell with the aid of a replication 
competent helper virus. DI particles have been demonstrated to persist in the lungs of SCID mice up to 16 days 
after challenge40. The persistence of such DI particles may explain the late regulation of miRNAs in the circulat-
ing leukocytes. Indeed, defective viral genomes (DVG) segments arising from especially the PA and PB1 gene 
segments have been shown to be recognised by RIG-I and may thus function as PAMPs, inducing a cytokine 
response (IFN-β , IL-6) through RIG-I also after the productive virus infection has vanished41,42. Although we did 
not observe significantly increased levels of IFNB1 or IL6 mRNA in the lungs of our animals at 14d pi (Skovgaard 
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et al. 2013), and we have found miRNAs in the lung tissue to primarily be regulated on days 1 and 3 (Brogaard et 
al., manuscript in preparation) in contrast to on day 14 in leukocytes, we cannot rule out that DI particles have 
persisted in a small number of cells, influencing the lung environment and as a consequence affecting the miRNA 
response in circulation.
Numerous pathways are activated in the cell upon IAV infection, including the Toll-like receptor, RIG-I-like 
receptor, NFκ B, and PI3K/AKT signaling pathways43, many of which are important in the induction and control 
of apoptosis. IAV infection induces apoptosis in host cells in vivo and in vitro and different viral proteins have 
been found to manipulate apoptotic signaling, including the non-structural proteins NS1 and PB1-F244,45 and 
the nucleoprotein NP46. Several studies have shown that IAV has evolved strategies to benefit from host apopto-
sis, which might otherwise be considered a host defence mechanism to limit virus replication and spread. Our 
pathway enrichment analysis revealed that many of the same pathways may be affected in circulating leukocytes 
both during and after IAV infection, including pathways related to apoptosis and cell cycle regulation. These 
pathways were enriched in gene target subsets of both up- and down-regulated miRNA, demonstrating that 
miRNA regulation of these pathways is complex and allows for both down-regulation as well as expression or 
even up-regulation of their target genes/pathways. Consequently, only small or even non-significant changes were 
observed in the expression of the genes selected as highly targeted by differentially expressed miRNAs, suggesting 
a role for miRNAs in fine-tuning gene expression rather than causing dramatic changes.
MTI analysis of miRNAs found to be significantly regulated in porcine leukocytes revealed that several of the 
most highly targeted genes are relevant for apoptosis and cell survival, including BCL2, MCL1, PTEN, AKT2, 
BRCA1, and TP53. This suggests that miRNA play a role in regulating apoptotic pathways after IAV infection, 
e.g. by targeting components of some of the same pathways that are directly affected by viral protein interaction. 
Consistent with this emphasis on apoptosis was the fact that we found caspase-1 and caspase-3 transcription to 
be up-regulated within the first 72 hours of infection. The pro-apoptotic transcription factor p53 (TP53) has pre-
viously been implicated in IAV-induced apoptosis, mediated by direct interaction with viral NP46. In accordance 
with the importance of this transcription factor, we found miRNAs targeting TP53 to be significantly regulated in 
circulating leukocytes. Other genes that were highly targeted by differentially expressed miRNAs include PTEN 
and BCL2, central players in cell survival and apoptosis44,47,48. BCL2 was heavily targeted by up-regulated miR-
NAs, whereas PTEN targeting was balanced between up- and down-regulated miRNAs. ssc-miR-29a was the only 
miRNA to be regulated at all three time points. The miR-29 family is well characterised and commonly described 
to be involved in cancers as tumor suppressors49. Among the targets for hsa-miR-29a-3p is PTEN, which was sig-
nificantly down-regulated at both 24 h and 14d pi. This is consistent with up-regulation of ssc-miR-29a at 14d pi, 
whereas up-regulation of ssc-miR-182 – another PTEN-targeting miRNA – may be a contributing factor to PTEN 
down-regulation at 24 h pi given that ssc-miR-29a is itself down-regulated at this time point.
In a previous study inhibition of miR-29a(-3p) in human hepatoma cell lines was shown to lead to 
up-regulation of PTEN at mRNA and protein levels, whereas overexpression of miR-29a down-regulated PTEN 
mRNA and protein50. Moreover, miR-29a inhibition negatively regulated phosphorylation of Akt (Protein Kinase 
B), which is an important step in the PI3K/AKT signaling pathway50.
Akt family member AKT2 as well as FOXO3A, a pro-apoptotic transcription factor (FoxO) downstream of 
PTEN and Akt, are also among the targets for hsa-miR-29a-3p. Despite being heavily targeted by up-regulated 
miRNAs at both 72 h and 14d pi (Supplementary Fig. S1), we saw no regulation of these two genes. It is however 
possible that Akt and FoxO protein functions are still affected by ssc-miR-29a regulation, given the effect that 
down-regulation of PTEN is likely to have on PTEN protein levels. Additionally, we observed up-regulation of 
hsa-miR-29a-3p targets BCL2 and MCL1 at 24 h pi, where ssc-miR-29a was down-regulated. Collectively, our 
results highlight the importance of ssc-miR-29a in relation also to influenza, especially after infection, where it is 
involved in regulation of apoptosis, as has been described previously primarily in cancers49.
In a previous study, we investigated mRNA expression in the lung tissue of the same animals as employed 
in the present study6, and could demonstrate that the chemokine transcripts CCL2, CCL3, and CXCL10 were 
highly up-regulated at 24 h and 72 h pi. This is in accordance with an expected need for recruitment of various 
immune cells to the affected lung tissue, in order to combat and contain the IAV infection. Here we show that the 
leukocytes available for extravasation display a miRNA expression profile specialised towards contributing to the 
control of cell survival and apoptosis in response to IAV infection.
Materials and Methods
Experimental design. This study employed blood samples from a previously described experimental chal-
lenge study6. All procedures and animal care activities were conducted in accordance with the guidelines and 
under approval of Good Clinical Practice (VICH GL9, CVMP/VICH/595/98), the Directive 2001/82/EC on the 
Community code relating to veterinary medicinal products and German Animal Protection Law. The proto-
col IDT A 03/2004 was approved by the Landesverwaltungsamt Sachsen-Anhalt, Germany (Reference Number: 
AZ 42502-3-401 IDT). All pigs (cross-bred Large White x German Landrace) were found seronegative for the 
following influenza virus strains by hemagglutination inhibition assay: A/sw/Haselünne/IDT2617/03 (H1N1), 
A/sw/Bakum/1832/00 (H1N2), A/sw/Bakum/IDT1769/03 (H3N2), A/sw/Denmark/13850/03 (H1N1), A/sw/
Denmark/12687/03 (H1N2). A/sw/Denmark/12687/03 (H1N2) was used as challenge strain; this virus has a 
European avian-like H1, and a European swine-like N229. This reassortant has been circulating in the Danish pig 
population since 2003, and has also been found in Germany, Poland, and Italy25. Briefly, a group of 12-week-old 
pigs were challenged by aerosol exposure to 6.0 l nebulised culture supernatant containing 104.55 TCID50/ml of the 
challenge strain. Blood samples were collected 2–4 hours (h) before challenge (n = 12), and at three time points 
after challenge: 24 h post infection (pi) (n = 12), 72 h pi (n = 9), and 14 days (d) pi (n = 6). Blood samples were 
stabilised by heparin (HEP tubes, Terumo). Lung material was collected for virus titration at 24 h (n = 3), 72 h 
(n = 3), and 14d pi (n = 6) and stored in RNAlater (Qiagen) at − 20 °C.
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Clinical signs and virus detection. Clinical signs and rectal temperature were recorded morning and 
afternoon until 72 h pi. A composite dyspnoea score was determined based on the following clinical signs as 
described previously6: 0 = breathing unaffected; 1 = increased respiratory frequency and moderate flank move-
ment; 2 = marked pumping breathing and severe flank movement; 3 = laboured breathing affecting the entire 
body, pronounced flank movement and substantial movements of the snout, 4 = severe breathing reflecting sub-
stantial lack of oxygen. Virus content of the lungs was quantified by titration in embryonated hens’ eggs on day 
one, three, and 14 after challenge as described previously51. The individual titers expressed in EID50/g lung tissue 
were determined in samples of pools from all lung lobes.
RNA extraction. Heparin stabilised whole blood samples were depleted of red blood cells using QIAamp 
hypotonic EL buffer (Qiagen), followed by centrifugation at 400 × g at 4 °C for 10 min. Pellets containing leuko-
cytes were resuspended in 600 μ l RLT buffer (Qiagen) and stored at − 80 °C, stabilising the RNA until extraction. 
For extraction, 300 μ l leukocyte suspension was mixed with 1 ml Trizol (Invitrogen) and incubated for 5 min at 
room temperature. RNA extraction was performed according to the manufacturer’s instructions (Invitrogen). 
Purity of extracted total RNA was assessed using UV absorption measured on a NanoDrop ND-1000 spectropho-
tometer (Saveen and Werner AB); average A260/280 and A260/230 ratios were 1.87 and 1.70, respectively. Total RNA 
was quantified by measuring the sample absorption at 260 nm; average RNA yield was 272 ng/μ l. RNA integrity 
was measured on an Agilent 2100 Bioanalyzer (Agilent Technologies) using the RNA 6000 Nano Kit (Agilent), 
yielding an average RNA integrity number (RIN) of 8.9.
miRCURY LNA Universal RT microRNA PCR. Initial screening for differentially expressed miRNAs dur-
ing the course of infection was performed on a subset of the samples from the experimentally challenged pigs: 
before challenge: n = 10; 24 h pi: n = 10; 72 h pi: n = 6. Screening was carried out using the Human Panel I, miR-
CURY LNATM (Exiqon). 20 ng total RNA was reverse transcribed in 20 μ l reactions using the miRCURY LNA™ 
Universal RT microRNA PCR, polyadenylation, and cDNA synthesis kit (Exiqon). Negative controls (minus 
RT) where the reverse transcriptase was replaced with water were included to check for contaminating genomic 
DNA. Diluted (1:100) cDNA was assayed in 10 μ l PCR reactions according to the protocol for miRCURY LNA™ 
Universal RT microRNA PCR (Exiqon). Each miRNA was assayed once by qPCR in the Human Panel I contain-
ing 375 miRNA assays including a non-template control (NTC). Amplification was performed in a LightCycler® 
480 Real-Time PCR System (Roche) in 384 well plates. LightCycler® 480 software was used to determine the 
quantification cycle (Cq) values and inspect amplification and melting curves. Data was normalised to the mean 
expression value of all miRNAs expressed in the individual sample.
cDNA synthesis, pre-amplification, and qPCR of miRNA. Reverse transcription of 100 ng total 
RNA was performed as described previously52. Briefly, reaction volumes of 10 μ l containing 1 μ M universal RT 
primer (5′ caggtccagtttttttttttttttvn3′ ), 100 ng total RNA, 1 μ l of 10X poly(A) polymerase buffer (New England 
BioLabs), 0.1 mM of ATP (New England BioLabs), 0.1 μ M of each deoxynucleotide (dATP, dCTP, dGTP, and 
dTTP) (Sigma-Aldrich), 100 units of MuLV reverse transcriptase (replaced with water for the minus RT control) 
(New England BioLabs), 1 unit of poly(A) polymerase (New England Biolabs, USA), and RNase-free water were 
prepared. cDNA was synthesised at 42 °C for 1 hour followed by enzyme inactivation at 95 °C for 5 min. Two rep-
licates of cDNA synthesis were performed per RNA sample (technical replicates). All primers used in this study, 
including the universal RT primer, were designed using the specifications described previously52 and purchased 
from Sigma-Aldrich. Relevant miRNAs were defined based on the miRCURY LNA™ panel screening, published 
findings, and database searches (miRTarBase v. 4.5 and TarBase v. 6.0) for miRNAs experimentally confirmed 
to target antiviral immune mediators previously found to be regulated during influenza infection. Whenever an 
annotated porcine miRNA (“ssc-miR-“) sequence was available in miRBase, this was used for primer design. If 
no porcine sequence was available, the corresponding human sequence homolog (“hsa-miR-“) was used. Primer 
sequences are shown in Supplementary Table S1. Pre-amplification was performed using TaqMan PreAmp 
Master Mix (Applied Biosystems). 200 nM pooled qPCR primer mix was prepared by combining each miRNA 
primer pair used in the qPCR setup. 5 μ l TaqMan PreAmp Master Mix, 2.5 μ l 200 nM pooled primer mix, and 
2.5 μ l cDNA was incubated at 95 °C for 10 min followed by 18 cycles of 95 °C for 15 s and 60 °C for 4 min. Residual 
primers were digested by adding 16 U of Exonuclease I (New England BioLabs), and incubated at 37 °C for 30 min 
followed by 80 °C for 15 min. qPCR was performed in Dynamic Array Integrated Fluidic Circuit chips (Fluidigm) 
in the BioMark HD real-time PCR instrument (Fluidigm). Pre-sample mix was prepared using the following 
components per sample: 3 μ l ABI TaqMan Gene Expression Master Mix (Applied Biosystems), 0.3 μ l 20X DNA 
Binding Dye Sample Loading Reagent (Fluidigm), 0.3 μ l 20X EvaGreen (Biotium, VWR – Bie & Berntsen), and 
0.9 μ l low EDTA TE Buffer (VWR – Bie & Berntsen). Pre-sample mix (4.5 μ l) was mixed with 1.5 μ l pre-amplified 
cDNA diluted 1:10 in low-EDTA TE-buffer (VWR – Bie & Berntsen), including a non-template control (cDNA 
replaced with water). Primer mix was prepared for each assay by mixing 3 μ l primer pair (forward and reverse, 
each 10 μ M) with 3 μ l 2X Assay Loading Reagent (Fluidigm). The following cycling parameters were used: 2 min 
at 50 °C, 10 min at 95 °C, followed by 35 cycles with denaturing for 15 s at 95 °C and annealing/elongation for 
1 min at 60 °C. Melting curves were generated after each run (from 60 °C to 95 °C, increasing 1°C/3 s).
Primer efficiencies were calculated for each assay based on three independent 5-fold dilution series made from 
a pool of all pre-amplified cDNA samples. Cq values were acquired using the Fluidigm Real-Time PCR Analysis 
software 3.0.2 (Fluidigm) and exported to GenEx5 (MultiD) for data processing including interplate calibration, 
correction for PCR efficiency, normalisation to mean expression of all miRNAs included in this study, and aver-
aging of cDNA technical repeats.
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cDNA synthesis, pre-amplification, and qPCR of mRNA. Extracted total RNA was converted 
into cDNA by reverse transcription of 50 ng RNA using the QuantiTect Reverse Transcription Kit (Qiagen) as 
described previously6, including minus RT controls. cDNA was diluted 1:3 in low-EDTA TE-buffer (VWR – 
Bie & Berntsen) prior to 15 cycles of pre-amplification followed by exonuclease treatment as described previ-
ously6. Pre-amplified cDNA was diluted 1:10 in low-EDTA TE-buffer (VWR – Bie & Berntsen) for use in qPCR. 
A panel of immune genes were chosen for transcriptional analysis based on published findings. Subsequently, 
based on target identification of the miRNAs found to be significantly regulated, additional transcriptional anal-
ysis was performed for the identified genes. qPCR primers were designed using Primer3 (http://bioinfo.ut.ee/
primer3-0.4.0/) as described previously53, and purchased from Sigma-Aldrich. Primer sequences and PCR effi-
ciencies are shown in Supplementary Table S1.
qPCR was carried out in Dynamic Array Integrated Fluidic Circuit chips on the BioMark HD real-time 
PCR platform (Fluidigm) as described previously6. Cq values were acquired using the Fluidigm Real-Time PCR 
Analysis software 3.0.2 (Fluidigm) and exported to GenEx5 (MultiD) for data processing, including interplate 
correction, correction for PCR efficiency, normalisation to reference genes, and averaging of cDNA technical 
repeats. Using geNorm and NormFinder algorithms (in GenEx), peptidylprolyl isomerase A (PPIA), hypox-
anthine phosphoribosyltransferase I (HRPT1), ribosomal protein L13a (RPL13A), TATA-box binding protein 
(TBP), and tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, zeta polypeptide 
(YWHAE) where identified as the most stably expressed reference genes out of six candidates and used for mRNA 
data normalisation.
Analysis for differential gene expression. For the initial screening study, normalised miRCURY LNATM 
data was log2 transformed before one-way ANOVA and Sidak correction (p < 0.0007) was employed to correct 
for multiple testing.
Normalised miRNA and mRNA qPCR expression data from Dynamic Array chips (Fluidigm) was log2 trans-
formed and tested for normal distribution prior to Student’s t-test (or Mann-Whitney U test if normality of data 
could not be demonstrated). miRNA and mRNA expression in sample groups (group means) from time points 
after challenge (24 h, 72 h, and 14d pi) was compared to expression in samples from before challenge (group 
mean); fold changes of expression was determined by dividing the mean expression level of a post-challenge 
group with the mean expression of the pre-challenge group. A change in expression level was considered sta-
tistically and biologically significant if p < 0.05 and the relative gene expression difference was > 1.5-fold (up or 
down) (miRNA) or > 2-fold (up- or down) (mRNA) between the groups compared.
A clustered heatmap was constructed to visualise miRNA gene expression, using the HemI 1.0.2 Heatmap 
Illustrator Toolkit employing hierarchical clustering.
miRNA target identification. Information on experimentally validated miRNA-target (i.e. mRNA) inter-
actions (MTIs) was available from miRTarBase v. 6.0. An initial overview of potentially affected cellular path-
ways was gained from performing KEGG pathway enrichment analysis by submitting the list of target genes 
obtained from miRTarBase to DAVID Bioinformatics Resources v. 6.7 tool. The Benjamini-Hochberg procedure 
was applied to control the false discovery rate (p < 0.05). Pathway enrichment analysis was performed on four 
subsets of target genes: target genes for 1) miRNAs up-regulated at 24 h and 72 h pi (i.e. during active infection), 
2) miRNAs down-regulated at 24 h and 72 h pi, 3) miRNAs up-regulated at 14d pi (i.e. after infection had cleared), 
and 4) miRNAs down-regulated at 14d pi.
MTIs for the sets of differentially expressed miRNAs in the three post-challenge groups were visualised using 
Cytoscape v. 3.2.1. This was achieved using the Cytoscape app CyTargetLinker v. 3.0.1; a CyTargetLinker RegIN 
containing only MTIs supported by strong experimental evidence as defined by miRTarBase was created, and 
applied for visualisation of MTI interaction networks in Cytoscape. KEGG pathway enrichment analysis and 
MTI networks were created using human miRNA and mRNA homologs, as miRTarBase does not contain porcine 
MTIs.
As available literature and miRNA databases are almost exclusively concerned with human miRNAs, a com-
parison of human and porcine miRNA sequences was made (miRBase v. 21) (summarised in Supplementary 
Table S2).
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